Sinovac Enters Exclusive Promotion Service Agreement with GlaxoSmithKline (China) Investment Co., Ltd.

Sinovac Biotech Ltd. , a leading provider of biopharmaceutical products in China, announced it has entered into an Exclusive Promotion Service Agreement with GlaxoSmithKline (China) Investment Co., Ltd. (or “GSK China”). GSK China and Sinovac will market and promote Anflu, a seasonal influenza vaccine developed and manufactured by Sinovac.
CNN Money via PR Newswire